Post-transplant Care
Post-transplant Care - Related Videos
08:15
Cervical Heterotopic Mouse Heart Transplantation using End-to-side Anastomosis Technique to Study Transplant Immunology
0 Views •
2026
This protocol presents a simplified, end-to-side suture anastomosis technique for murine cervical heart transplantation, providing a robust and reproducible model for studying transplant immunology.
08:58
Murine Kidney Transplant Technique
0 Views •
Cited by 8 •
2015
The goal of this manuscript is to describe the steps required to perform a kidney transplant in a mouse, paying particular attention to the details of the arterial anastomosis.
10:27
Murine Heterotopic Heart Transplant Technique
0 Views •
Cited by 19 •
2014
The manuscript describes the steps required to perform the heterotopic heart transplant in the mouse.
07:59
Murine Full-thickness Skin Transplantation
0 Views •
Cited by 41 •
2017
Murine full-thickness skin transplantation is a well-established model to study rejection in an alloimmune setting. Here, we provide a tutorial of each step involved in performing a BALB/c-->C57BL/6 full-thickness skin transplant.
06:42
Murine Skin Transplantation
0 Views •
Cited by 36 •
2008
Allogeneic skin transplantation is a standard model to assay host T cell responses to MHC-disparate donor antigens. This video-article provides a visual tutorial of each step involved in performing a BALB/c-->C57BL/6 skin transplant.
FAQs
Immunosuppressive therapy limits the immune system’s recognition of donor antigens, which are biological features that can identify the graft as non-self. Reducing this recognition lowers the likelihood that immune responses will damage transplanted tissue. The approach does not eliminate immune activity entirely, because maintaining an appropriate balance is necessary to avoid complications from excessive suppression.
Preventing rejection requires enough immunosuppression to control immune recognition of donor tissue, but excessive suppression can increase the risk of infection and treatment-related complications. For that reason, care teams interpret organ function, symptoms, laboratory results, and medication blood concentrations together. This balance allows therapy to remain protective while limiting avoidable harm during recovery and long-term follow-up.
Organ function provides a central biological indicator of graft status, while symptoms and laboratory findings add complementary evidence. Changes across these measures can help distinguish stable recovery from possible rejection or other complications. Interpreting them alongside medication concentrations also shows how host-donor interactions and immune control are influencing the transplant outcome over time.
Follow-up combines clinical assessment with laboratory testing and review of medication use. Care teams examine organ function, blood concentrations of immunosuppressive drugs, symptoms, and other test results. They use the combined findings to identify possible rejection, infection, or treatment-related complications and to determine whether medication doses should be adjusted during ongoing care.
Consistent medication adherence supports the intended level of immune suppression and helps maintain protection against rejection. Missed or inconsistent treatment can complicate interpretation of symptoms, laboratory results, and blood concentrations, making dose management more difficult. Patient education therefore forms an important part of follow-up, reinforcing how daily treatment connects with graft preservation and monitoring.
Dose adjustments may be considered when organ function, blood drug concentrations, symptoms, or other test results indicate that the current regimen needs review. A change may help address concern about rejection risk or reduce treatment-related complications associated with excessive immune suppression. Continued testing after adjustment supports evaluation of graft function and the longer-term transplant outcome.